[levothyroxine And The Problem Of Interchangeability Of Drugs With Narrow Therapeutic Index].

dc.creatorWard, Laura Sterian
dc.date2011-Oct
dc.date2015-11-27T13:22:04Z
dc.date2015-11-27T13:22:04Z
dc.date.accessioned2018-03-29T01:14:12Z
dc.date.available2018-03-29T01:14:12Z
dc.identifierArquivos Brasileiros De Endocrinologia E Metabologia. v. 55, n. 7, p. 429-34, 2011-Oct.
dc.identifier1677-9487
dc.identifier
dc.identifierhttp://www.ncbi.nlm.nih.gov/pubmed/22147090
dc.identifierhttp://repositorio.unicamp.br/jspui/handle/REPOSIP/199706
dc.identifier22147090
dc.identifier.urihttp://repositorioslatinoamericanos.uchile.cl/handle/2250/1299939
dc.descriptionThe exchange of a prescribed drug by other similar, by generic products and even by custom products has become common practice in our country, often ignoring basic tenets of bioequivalence, interchangeability, stability and characteristics of the pharmaceutical compounds. In the case of drugs of narrow therapeutic index, such as levothyroxine, these problems are intensified, putting the effectiveness of treatment and patient health at serious risk. We review the pertinent legislation, emphasizing the characteristics of levothyroxine and adverse effects that limit the interchangeability of the compound.
dc.description55
dc.description429-34
dc.languagepor
dc.relationArquivos Brasileiros De Endocrinologia E Metabologia
dc.relationArq Bras Endocrinol Metabol
dc.rightsaberto
dc.rights
dc.sourcePubMed
dc.subjectAdverse Drug Reaction Reporting Systems
dc.subjectBrazil
dc.subjectDrug Approval
dc.subjectDrug Substitution
dc.subjectDrugs, Generic
dc.subjectHumans
dc.subjectTherapeutic Equivalency
dc.subjectThyroid Hormones
dc.subjectThyroxine
dc.title[levothyroxine And The Problem Of Interchangeability Of Drugs With Narrow Therapeutic Index].
dc.typeArtículos de revistas


Este ítem pertenece a la siguiente institución